Summary of COVID-19 gabapentin studies

1. Soltani et al., The effectiveness of gabapentin and gabapentin/montelukast combination compared with dextromethorphan in the improvement of COVID‐19‐ related cough: A randomized, controlled clinical trial

129 patient gabapentin late treatment RCT: 11% longer hospitalization (p=0.23) and 97% worse recovery (p<0.0001).
RCT 180 hospitalized COVID-19 patients showing improved cough symptoms and shorter hospitalization with montelukast/gabapentin compared to gabapentin. For gabapentin vs. dextromethorphan there was no significant difference in hospitalization and reduced improvement in cough symptoms.
Jul 2022, The Clinical Respiratory J., https://onlinelibrary.wiley.com/doi/10.1111/crj.13529, https://c19p.org/soltani2gbp